<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881294</url>
  </required_header>
  <id_info>
    <org_study_id>CTP1S23031H3</org_study_id>
    <nct_id>NCT02881294</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Single-center, Open-label, Single-dose Study to Evaluate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of Orally Administered SUVN-G3031 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suven Life Sciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suven Life Sciences Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effect of Food, Gender, and Age on the
      Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under concentration (AUC)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SUVN-G3031 tablets single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gender Effect</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SUVN-G3031 tablets single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Effect</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SUVN-G3031 tablets single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUVN-G3031</intervention_name>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_label>Gender Effect</arm_group_label>
    <arm_group_label>Age Effect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female aged 18 to 45 years with a BMI between 18 and 30 kg/m2,
             (inclusive) for food and gender effect

          -  Healthy male aged 60 to 70 years with a BMI between 18 and 32 kg/m2, (inclusive) for
             age effect

        Exclusion Criteria:

          -  History or presence of GI, hepatic, or renal disease or any other condition known to
             interfere with absorption, distribution, metabolism, or excretion of drugs as judged
             by Investigator.

          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks
             of the first administration of the study drug.

          -  Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV) antibody

          -  History of any important clinically significant disease or disorder which, in the
             opinion of the Investigator, may either put the subject at risk because of
             participation in the study, or influence the results or the subject's ability to
             participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quintiles</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

